A Clinical Study to Evaluate Single-agent Therapy of BR113 for Injection in Patients With Advanced Solid Tumors

This is a Phase I, multicenter, open-label, single-arm and first-in-human clinical study of BR113 for injection. The study objectives are to evaluate the safety, tolerability, pharmacokinetic profile, anti-tumor activity and immunogenicity of BR113 for injection in patients with advanced malignancies.

NCT Number	NCT07753590
Lead Sponsor	BioRay Pharmaceutical Co., Ltd.
Conditions	Advanced Solid Tumors
Enrollment	258 participants
Start Date	2026-08
Primary Completion	2030-02 (estimated)
Study Completion	2030-12 (estimated)
Updated on ClinicalTrials.gov	2026-08-07